Launch of the HiMax Plus Widebody™ Fixation System for Foot Fusions

CrossRoads® Extremity Systems Reports HiMax® Plus Offers Greater Stability and a Lower Profile Coupled with Market Leading Compression

CrossRoads® Extremity Systems, the global leader in Staple Compression Plates(SCP) and nitinol technology for the lower extremities, announced it has received FDA clearance and launched the HiMax® Plus Widebody Fixation System.

HiMax Plus is the only foot bone fusion system on the market to provide flush insertion, market-leading compression, and a wide bridge for enhanced stability. The features work in conjunction to provide improved implant performance with more efficiency in the operating room than alternative technologies. HiMax® Plus is CrossRoads’ latest addition to its Comprehensive Nitinol System.

Chad Hollis, VP of Research and Development and Co-Founder, stated “HiMax Plus shows our continued commitment to be the leader in the development of nitinol applications for the lower extremities. The HiMax family is born from years of fine-tuning and we believe the addition of HiMax Plus gives surgeons an enhanced nitinol implant that will be an optimal solution for all types of fusions.” CrossRoads will unveil this new system at the American College of Foot and Ankle Surgeons (ACFAS) Annual 2020 Meeting taking place in San Antonio, TX February 19th through February 22nd. CrossRoads will be exhibiting at booth #143.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version